A landmark analysis at the 5th Rd cycle in arm A and at ASCT in arm B showed a trend for improved PFS with ASCT as well as improved OS [ 38 , 43 , 44 ].
← all excerpts
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.
1
—
—